Open Access

CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways

  • Authors:
    • Kiyoko Nakamura
    • Yoshito Terai
    • Akiko Tanabe
    • Yoshihiro J. Ono
    • Masami Hayashi
    • Kazuya Maeda
    • Satoe Fujiwara
    • Keisuke Ashihara
    • Michihiko Nakamura
    • Yoshimichi Tanaka
    • Tomohito Tanaka
    • Satoshi Tsunetoh
    • Hiroshi Sasaki
    • Masahide Ohmichi
  • View Affiliations

  • Published online on: April 19, 2017     https://doi.org/10.3892/or.2017.5583
  • Pages: 3189-3200
  • Copyright: © Nakamura et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The degree of peritoneal dissemination and chemotherapy-resistant tumors is related to the prognosis in patients with advanced-stage ovarian cancer. The epithelial-mesenchymal-transition (EMT) is a multifaceted pathological program that endows cancer cells with the ability to invade and disseminate. CD24 is frequently overexpressed in various human cancers and is correlated with a poor prognosis. We herein examined the functions of CD24 in human ovarian cancer cell lines and evaluated how it contributes to the molecular mechanism underlying the regeneration of cancer stem-like cells (CSCs) through the EMT mechanism in ovarian carcinoma. We demonstrated that CD24 was expressed in 70.1% of primary ovarian carcinoma tissues, which were obtained from 174 patients, and that the expression of CD24 was an independent predictor of survival in patients with ovarian cancer. The expression of CD24 has been found to be correlated with the FIGO stage, presence of peritoneal and lymph node metastasis. CD24 induces the EMT phenomenon, which is involved in cell invasion, the highly proliferative phenotype, colony formation and which is associated with cisplatin resistance and the properties of CSCs, via the activation of PI3K/Akt, NF-κB and ERK in Caov-3 cisplatin-resistant cell lines. CD24-positive ovarian carcinomas have been shown to have a greater potential for intra-abdominal tumor cell dissemination in in vivo models. Our findings suggest that CD24 induced the EMT phenomenon in ovarian cancer, and that CD24 amplified cell growth-related intracellular signaling via the PI3K/Akt and MAPK pathways by affecting the EMT signal pathways. We believe that CD24 is a key molecule of metastatic progression in the EMT phenomenon and a promising therapeutic target for advanced ovarian cancer.
View Figures
View References

Related Articles

Journal Cover

June 2017
Volume 37 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Nakamura, K., Terai, Y., Tanabe, A., Ono, Y.J., Hayashi, M., Maeda, K. ... Ohmichi, M. (2017). CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways. Oncology Reports, 37, 3189-3200. https://doi.org/10.3892/or.2017.5583
MLA
Nakamura, K., Terai, Y., Tanabe, A., Ono, Y. J., Hayashi, M., Maeda, K., Fujiwara, S., Ashihara, K., Nakamura, M., Tanaka, Y., Tanaka, T., Tsunetoh, S., Sasaki, H., Ohmichi, M."CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways". Oncology Reports 37.6 (2017): 3189-3200.
Chicago
Nakamura, K., Terai, Y., Tanabe, A., Ono, Y. J., Hayashi, M., Maeda, K., Fujiwara, S., Ashihara, K., Nakamura, M., Tanaka, Y., Tanaka, T., Tsunetoh, S., Sasaki, H., Ohmichi, M."CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways". Oncology Reports 37, no. 6 (2017): 3189-3200. https://doi.org/10.3892/or.2017.5583